国产利妥昔单抗治疗弥漫大B细胞淋巴瘤的临床疗效和安全性

Clinical Efficacy and Safety of Domestic Rituximab in Treatment of Diffuse Large B Cell Lymphoma

目的:分析国产利妥昔单抗治疗弥漫大B细胞淋巴瘤的临床疗效和安全性。方法:回顾性分析2019年5月-2021年10月江苏省徐州市中心医院血液科收治的43例弥漫大B细胞淋巴瘤患者的临床资料。使用国产利妥昔单抗治疗的21例为观察组,使用原研利妥昔单抗治疗的22例为对照组。患者均采用R/H-CHOP方案(原研/国产利妥昔单抗、环磷酰胺、蒽环类、长春碱类、糖皮质激素)治疗,比较两组患者治疗效果及安全性。结果:两组患者客观缓解率(ORR)比较,差异无统计学意义(P>0.05);两组患者白细胞减少、血小板减少、转氨酶升高、胃肠道反应、感染、发热发生率比较,差异无统计学意义(P>0.05)。结论:国产利妥昔单抗治疗弥漫大B细胞淋巴瘤临床疗效和安全性良好,可成为更多患者的治疗选择。

Objective: To analyze the clinical efficacy and safety of domestic rituximab in treatment of diffuse large B cell lymphoma. Methods: Clinical data of 43 patients with diffuse large B cell lymphoma who were admitted to Xuzhou Central Hospital from May 2019 to October 2021 were retrospectively analyzed. Among them, 21 patients were treated with domestic rituximab as observation group, and 22 patients were treated with original rituximab as control group. All patients were treated with R/H-CHOP regimen(original/domestic rituximab plus cyclophosphamide plus anthracycline plus vinblastine plus glucocorticoid). The treatment effect and safety in two groups were compared. Results: There was no statistically significant difference in objective response rate(ORR) between the two groups(P>0.05). There was no statistically significant difference in the incidence of Leukopenia, thrombocytopenia, elevated aminotransferases, gastrointestinal reactions, infection, fever between the two groups(P>0.05). Conclusions: Domestic rituximab reveals good clinical efficacy and safety in treating diffuse large B cell lymphoma, which can be a treatment option for more patients.